Samyang Holdings and LG Chem announced on the 20th that they signed a strategic partnership agreement to apply Samyang Holdings’ independent drug delivery technology to the development of mRNA-based anti-cancer drugs.
This contract is an unrestricted technology transfer contract, and Samyang Holdings provides LG Chem with the related technology and composition of ‘NanoReady’ mRNA delivery system developed by itself, and LG Chem combines it to maximize of anticancer efficacy, an mRNA-based breakthrough. plan to discover the material.
According to the contract, LG Chem will pay Samyang Holdings a down payment and milestones for each stage of development.
mRNA is genetic material that contains information to make a specific protein in cells, and in order to develop it as a therapeutic agent, a ‘drug delivery system’ that enables efficient protein expression by delivering it safely to cells is essential.
NanoReady is Samyang Holdings’ unique drug delivery technology and is characterized by its high flexibility.
The compounding process can be simplified by mixing the efficacious mRNA substance developed by LG Chem with the pre-made delivery composition, which is expected to be effective in shortening the development period of new drugs and developing personalized treatments.
Lee Yeong-joon, CEO of Samyang Holdings, said, “LG Chem is a company with excellent new drug development capabilities and multiple new drug pipelines, and we intend to further strengthen our cooperative relationship with this contract as an opportunity.” “We will contribute to improving the quality of life of patients suffering from cancer.”
Son Ji-woong, head of LG Chem’s life science business division, said, “We will maximize the results of collaboration between the two companies to deliver advanced mRNA anti-cancer drugs to patients around the world.”
Meanwhile, Samyang Holdings Biopharmaceuticals Group has been focusing its capabilities on research on drug delivery systems (DDS) that safely and effectively deliver drugs to the human body based on bioabsorbable polymer technology and proprietary patent technology.
Recently, in addition to NanoReady, the company is accelerating the development of various mRNA delivery systems for preventive vaccines and rare disease treatments, and plans to contribute to the development of various therapeutic agents through long-term selective mRNA delivery systems that overcome limitations of existing mRNA delivery systems.
